Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82. https://doi.org/10.1182/blood.2021011281.
Brissot E, Labopin M, Labussiere H, Fossard G, Chevallier P, Guillaume T, et al. “Post-transplant cyclophosphamide versus antithymocyte globulin after reduced-intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA-matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.” Blood Cancer J. 2024;14:31. https://doi.org/10.1038/s41408-024-00990-3.
Gomez-Centurion I, Martin Rojas RM, Bailen R, Munoz C, Sabell S, Oarbeascoa G, et al. Graft function decline after haploidentical stem cell transplantation with post-transplant cyclophosphamide. Ann Hematol. 2023;102:1561–7. https://doi.org/10.1007/s00277-023-05206-5.
Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B, et al. Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplant cyclophosphamide: risk of graft failure, reduced graft function, and impact on outcome. Biol Blood Marrow Transpl. 2019;25:1395–406. https://doi.org/10.1016/j.bbmt.2019.02.020.
Stem Cell Clinical Trials Collaborator G. Allogeneic peripheral blood stem cell versus bone marrow transplantation for the treatment of hematologic malignancies: individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87. https://doi.org/10.1200/JCO.2005.09.020.
Remberger M, Gronvold B, Ali M, Mattsson J, Egeland T, Lundin KU, et al. CD34(+) cell abundance is important in hematopoietic stem cell transplantation using peripheral blood stem cells from sibling donors. Clin Hematol Int. 2020;2:74–81. https://doi.org/10.2991/chi.d.200221.001.
Sohn SK, Kim JG, Kim DH, Lee NY, Suh JS, Lee KB. Effect of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transpl. 2003;31:967–72. https://doi.org/10.1038/sj.bmt.1704042.
Remberger M, Torlen J, Ringden O, Engstrom M, Watz E, Uhlin M, et al. Impact of total nuclear cell mass and CD34(+) cell mass on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:889–93. https://doi.org/10.1016/j.bbmt.2015.01.025.
Mata JR, Zahurak M, Rosen N, DeZern AE, Jones RJ, Ambinder AJ. Incidence, risk factors, and outcomes of graft failure in patients receiving nonmyeloablative allogeneic hematopoietic cell transplants with posttransplant cyclophosphamide. Transplant Cell Ther 2024. https://doi.org/10.1016/j.jtct.2024.03.018.
Wang Y, Kong Y, Zhao HY, Zhang YY, Wang YZ, Xu LP, et al. Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label, randomized trial. BMC Med. 2022;20:140. https://doi.org/10.1186/s12916-022-02338-9.
Gao WH, Zhu JY, Wang LN, Wan M, Wang L, Devillier R, et al. “Post-transplant cyclophosphamide in combination with tacrolimus and low-dose post-transplant antithymic globulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from familial haploidentical donors: a single-center analysis.” Front Med (Lausanne). 2023;10:1140217. https://doi.org/10.3389/fmed.2023.1140217.
Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, et al. High content of CD3+ and CD34+ peripheral blood stem cell grafts is associated with an increased risk of graft-versus-host disease but has no beneficial effect on disease control after unrelated transplantation from matched unrelated donors for acute myeloid leukemia – an analysis by the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation. Oncotarget. 2016;7:27255–66. https://doi.org/10.18632/oncotarget.8463.
Arabic
Chinese (Simplified)
Dutch
English
French
German
Italian
Portuguese
Russian
Spanish